News | December 23, 2025
Zydus Partners with Bioeq for US commercialisation rights for Nufymco
NUFYMCO BLA has been approved by the USFDA
NUFYMCO BLA has been approved by the USFDA
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
This recognition demonstrate excellence in intellectual property (IP) value creation.
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Expands bioprocessing footprint across Asia
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
Subscribe To Our Newsletter & Stay Updated
